Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02297945 | Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome | PHASE3 | COMPLETED | 50 | — | — | Apr 1, 2015 | Apr 29, 2020 | Sep 25, 2020 | 36 | Belgium, Germany +6 |
| Arm | Type | Description |
|---|---|---|
| Metyrapone | EXPERIMENTAL | Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved. |
| Name | Type | Description |
|---|---|---|
| metyrapone | DRUG | Single arm study |
Inclusion Criteria: 1\. Patients with endogenous Cushing's syndrome: * Cushing disease patients with persistent or recurrent disease (after pituitary surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to defer surgery; * Patients with ectopic ACTH syndrome (either occ...